{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:47:32Z","timestamp":1789040852487,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of proteinuria restricts the dose of anti-angiogenic agents, thereby reducing their efficacy. Thus, this retrospective study was undertaken to identify predictive factors of the development of angiogenesis inhibitor-induced proteinuria, and to elucidate if there is a difference in the likelihood of proteinuria among anti-angiogenic agents or cancer types, to help guide future strategies to improve the safety, efficacy, and quality of life of patients receiving chemotherapy. Between April 2014 and February 2019, 124 cancer patients at our outpatient chemotherapy center who were receiving chemotherapy with bevacizumab, ramucirumab, or aflibercept were enrolled. Variables related to the development of proteinuria were extracted from the patients\u2019 clinical records and used for regression analysis. The level of the proteinuria was evaluated based on CTCAE version 5. Multivariate ordered logistic regression analysis was performed to identify predictive factors for the development of proteinuria. The Wilcoxon\/Kruskal-Wallis test was used to identify significant differences between groups. Significant factors identified included systolic blood pressure (SBP) [odds ratio (OR)\u2009=\u20091.031, 95% confidence interval (CI)\u2009=\u20091.005\u20131.058; <jats:italic>P<\/jats:italic>\u2009=\u20090.0197], number of cycles (OR\u2009=\u20091.049, 95% CI\u2009=\u20091.018\u20131.082; <jats:italic>P<\/jats:italic>\u2009=\u20090.0019), and calcium channel blocker use (OR\u2009=\u20092.589, 95% CI\u2009=\u20091.090\u20136.146; <jats:italic>P<\/jats:italic>\u2009=\u20090.0311). There was no difference among the three anti-angiogenic agents (<jats:italic>P<\/jats:italic>\u2009=\u20090.4969) or among cancer types (<jats:italic>P<\/jats:italic>\u2009=\u20090.2726) in the likelihood of proteinuria. In conclusion, SBP, number of cycles, and calcium channel blocker use were identified as significant predictors of the development of angiogenesis inhibitor-induced proteinuria. There was no difference among the three anti-angiogenic agents or among cancer types.<\/jats:p>","DOI":"10.1038\/s41598-020-58994-5","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T11:04:48Z","timestamp":1580987088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Yuko","family":"Kanbayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigo","family":"Otsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"58994_CR1","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar, F. F. et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 23, 3706\u201312 (2005).","journal-title":"J. Clin. Oncol."},{"key":"58994_CR2","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542\u201350 (2006).","journal-title":"N. Engl. J. Med."},{"key":"58994_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u201335 (2014).","journal-title":"Lancet Oncol."},{"key":"58994_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz, G. et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 15, 1269\u201378 (2014).","journal-title":"Lancet Oncol."},{"key":"58994_CR5","doi-asserted-by":"publisher","first-page":"e687","DOI":"10.1634\/theoncologist.2018-0824","volume":"24","author":"A Fern\u00e1ndez Montes","year":"2019","unstructured":"Fern\u00e1ndez Montes, A. et al. Juez Martel, L\u00f3pez Flores M, Carmona-Bayonas A. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. Oncologist. 24, e687\u2013e695 (2019).","journal-title":"Oncologist."},{"key":"58994_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000437253","volume":"60","author":"O Abdel-Rahman","year":"2014","unstructured":"Abdel-Rahman, O. & ElHalawani, H. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis. Chemotherapy. 60, 325\u201333 (2014).","journal-title":"Chemotherapy."},{"key":"58994_CR7","doi-asserted-by":"publisher","first-page":"e111839","DOI":"10.1371\/journal.pone.0111839","volume":"9","author":"L Peng","year":"2014","unstructured":"Peng, L. et al. Incidence and risk of proteinuria with aflibercept in cancer patients: a meta-analysis. PLoS One. 9, e111839 (2014).","journal-title":"PLoS One."},{"key":"58994_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1651-2227.2006.00178.x","volume":"96","author":"AK Akobeng","year":"2007","unstructured":"Akobeng, A. K. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 96, 644\u20137 (2007).","journal-title":"Acta Paediatr."},{"key":"58994_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu, S., Kim, C., Baer, L. & Zhu, X. Bevacizumab increases risk for severe proteinuria in cancer patients. J. Am. Soc. Nephrol. 21, 1381\u20139 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"58994_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000365156","volume":"40","author":"RA Lafayette","year":"2014","unstructured":"Lafayette, R. A. et al. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials. Am. J. Nephrol. 40, 75\u201383 (2014).","journal-title":"Am. J. Nephrol."},{"key":"58994_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu, X., Wu, S., Dahut, W. L. & Parikh, C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49, 186\u201393 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"58994_CR12","doi-asserted-by":"publisher","first-page":"e16236","DOI":"10.1097\/MD.0000000000016236","volume":"98","author":"T Fujii","year":"2019","unstructured":"Fujii, T., Kawasoe, K., Tonooka, A., Ohta, A. & Nitta, K. Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review. Med. 98, e16236 (2019).","journal-title":"Med."},{"key":"58994_CR13","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","volume":"49","author":"BA George","year":"2007","unstructured":"George, B. A., Zhou, X. J. & Toto, R. Nephrotic syndrome after bevacizumab: case report and literature review. Am. J. Kidney Dis. 49, e23\u20139 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"58994_CR14","first-page":"217","volume":"68","author":"H Teramachi","year":"2013","unstructured":"Teramachi, H. et al. Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy. Pharmazie. 68, 217\u201320 (2013).","journal-title":"Pharmazie."},{"key":"58994_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00280-019-03876-5","volume":"84","author":"T Hirai","year":"2019","unstructured":"Hirai, T., Shuji, Y., Takiyama, M., Hanada, K. & Itoh, T. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis. Cancer Chemother. Pharmacol. 84, 195\u2013202 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"58994_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1681\/ASN.2007060693","volume":"19","author":"L Vogt","year":"2008","unstructured":"Vogt, L., Waanders, F., Boomsma, F., de Zeeuw, D. & Navis, G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol. 19, 999\u20131007 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"58994_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrneph.2012.281","volume":"9","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink, H. J., de Borst, M. H., Bakker, S. J. & Navis, G. J. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. Nat. Rev. Nephrol. 9, 112\u201321 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"58994_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-018-3580-1","volume":"81","author":"S Nihei","year":"2018","unstructured":"Nihei, S. et al. Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. Cancer Chemother. Pharmacol. 81, 1051\u20131059 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"58994_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/cam4.701","volume":"5","author":"A Nakaya","year":"2016","unstructured":"Nakaya, A. et al. Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. Cancer Med. 5, 1381\u20137 (2016).","journal-title":"Cancer Med."},{"key":"58994_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1681\/ASN.2004080656","volume":"16","author":"P Muntner","year":"2005","unstructured":"Muntner, P., He, J., Astor, B. C., Folsom, A. R. & Coresh, J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J. Am. Soc. Nephrol. 16, 529\u201338 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"58994_CR21","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold, D. et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann. Oncol. 28, 2932\u20132942 (2017).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58994-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T15:11:56Z","timestamp":1672672316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-58994-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["58994"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-58994-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,6]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2011"}}